Cefpimizole
- Product Name
- Cefpimizole
- CAS No.
- 84880-03-5
- Chemical Name
- Cefpimizole
- Synonyms
- A-1370;U 63196;Cefpimizol;CEFPIMIZOLE;Cefpimizole USP/EP/BP;1-[[(6R)-2-Carboxylato-7α-[[(R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)pyridinium;Pyridinium, 1-[[(6R,7R)-2-carboxy-7-[[(2R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt;Pyridinium,1-[[(6R,7R)-2-carboxy-7-[[(2R)-2-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-,inner salt;(6R,7R)-7-[[(2R)-2-[(5-carboxy-1H-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-3-[[4-(2-sulfonatoethyl)pyridin-1-ium-1-yl]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;Pyridinium, 1-[[2-carboxy-7-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt, [6R-[6α,7β(R*)]]-
- CBNumber
- CB9314975
- Molecular Formula
- C28H26N6O10S2
- Formula Weight
- 670.67
- MOL File
- 84880-03-5.mol
N-Bromosuccinimide Price
- Product number
- API0010963
- Product name
- CEFPIMIZOLE
- Purity
- 95.00%
- Packaging
- 25MG
- Price
- $15015
- Updated
- 2021/12/16
- Product number
- MT-49085
- Product name
- Cefpimizole
- Purity
- 98%
- Packaging
- 0.5g
- Price
- $910
- Updated
- 2021/12/16
Cefpimizole Chemical Properties,Usage,Production
Description
Cefpimizole sodium is a third-generation cephalosporin with a spectrum of activity somewhat narrower than cefotaxime and cefoperazone.
Originator
Ajinomoto (Japan)
Uses
Antibacterial.
Definition
ChEBI: Cefpimizole is a peptide.
brand name
Ajicef; Renilan
Antimicrobial activity
A semisynthetic parenteral cephalosporin. It exhibits modest
activity compared to other antipseudomonal cephalosporins.
Like cefoperazone, it is susceptible to many enterobacterial
β-lactamases. In volunteers receiving 0.1–1 g intramuscularly,
mean peak plasma concentrations reached 15–20 and
35–40 mg/L, respectively. There was no accumulation when
the dose was repeated every 8 h for 7 days. No metabolites
have been detected. The plasma elimination half-life is 1.8–
2.1 h. The principal route of elimination is renal, 70–80%
being recovered unchanged in the urine.
Significant pain at the site of infection has been a prominent
adverse event. It is no longer widely available.